Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis… read more.
Fear can be used strategically in public health messaging to encourage people to quit smoking and avoid tobacco use, according to a joint study by researchers from the… read more.
Eli Lilly and Company announced positive topline results from the Phase III LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary… read more.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment… read more.
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research… read more.
New research presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns… read more.
A recent study shows that the rapid increase of new nicotine products and the influence of the tobacco industry are perceived to significantly hinder the European countries’ ability… read more.
For years, a central debate in tobacco policy has been whether taxing e-cigarettes (ECs) might unintentionally drive vapers back to traditional cigarettes. A new study published in Health Economics suggests… read more.
While cigarette exposures are decreasing for young children, electronic nicotine products are putting toddlers at new risk of inhalation, according to Rutgers Health researchers. Their study, published in JAMA Network… read more.
GSK plc announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult… read more.
A new overview of the best available evidence worldwide for smoking cessation has found that nicotine‑containing e‑cigarettes appear to be more effective for smoking cessation than other interventions… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
